Medical Pharmacology: Hypothalamic and Pituitary Practice Questions

G protein-coupled hormone receptor system(s):
1. GHRH
2. somatostatin
3. thyrotropin-releasing hormone
4. FSH
5. all the above
Primary target organ for adrenocorticotropin (ACTH):
1. liver
2. adrenal cortex
3. thyroid
4. gonads
5. breast
Primary target organ for leutinizing hormone:
1. liver
2. adrenal cortex
3. thyroid
4. gonads
5. breast
Hypothalamic hormone linked to the pituitary hormone prolactin
1. growth hormone releasing hormone
2. corticotropin-releasing hormone
3. dopamine
4. gonadotropin-releasing hormone
5. somatotropin release-inhibiting hormone (somatostatin, SRIH)
In short children with subnormal GH responses to oral L-DOPA, a normal response following GHRH infusion suggests:
1. pituitary or hypothalamic dysfunction
2. growth hormone deficiency due to hypothalamic dysfunction
3. both
4. neither
Somatostatin vs. octreotide: longer serum half-life:
1. somatostatin
2. octreotide
Clinical uses for the somatostatin analog, octreotide:
1. acute bleeding control from esophageal varices
2. carcinoid syndrome symptoms
3. gastrinoma symptoms
4. acromegaly symptoms
5. all the above
Effects of growth hormone:
1. adipose tissue lipolysis
2. skeletal muscle atrophy
3. both
4. neither
Most common cause of congenital growth hormone deficiency:
1. craniopharyngiomas and other hypophyseal-pituitary region disease
2. lack of hypothalamic growth hormone-releasing factors
3. high-level of serum growth hormone antibodies
Recombinant DNA technology growth hormone for pharmacological use:
1. somatotropin
2. somatrem
3. both
4. neither
Clinical factors that may impair growth hormone response:
1. hypothyroidism
2. diabetes insipidus
3. diabetes mellitus
4. A & B
5. A, B & C